Caris Life Sciences Celebrates Milestone of Over 1,000 Published Studies in Precision Medicine

Celebrating a Major Milestone in Precision Medicine

Caris Life Sciences®, a leading company in next-generation AI technology and precision medicine, has recently exceeded an impressive milestone by publishing more than 1,000 studies since 2015. This landmark achievement showcases the company’s dedication to advancing the field of precision medicine, particularly in the area of cancer treatment. Collaborating with multiple research partners, Caris has made tremendous progress through peer-reviewed manuscripts, scientific posters, and abstracts.

In 2024 alone, Caris successfully published over 70 peer-reviewed studies and more than 120 posters and abstracts, emphasizing their commitment to collaboration with renowned cancer centers, including those within the Caris Precision Oncology Alliance™ (POA). This collective effort highlights the importance of teamwork in pushing the boundaries of science and improving patient outcomes.

David Spetzler, MS, PhD, MBA, President of Caris Life Sciences, stated, “Reaching this milestone is a testament to our team’s dedication to advancing science and global knowledge of cancer biology through our collaborations with leading cancer centers and research institutions.” He highlighted that great achievements in science require collaboration among clinical experts, tumor biologists, and data scientists, which is precisely what the Caris POA facilitates.

Caris has been at the forefront of innovative research in comprehensive molecular profiling for tissue and blood samples. Their studies delve into the clinical applications of liquid biopsies and the identification of clonal hematopoiesis, with findings regularly featured in prestigious journals and scientific conferences. These contributions enhance Caris’s reputation as a leader in precision oncology.

George W. Sledge, Jr., MD, EVP and Chief Medical Officer of Caris, emphasized the significance of their findings in guiding personalized treatment strategies. “Our goal is to provide clinicians and patients with the highest quality information to guide personalized treatment plans and improve outcomes,” he said.

Among the notable publications released in 2024, a study published in the journal Nature Cancer addressed tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy. By analyzing clinical data from over 70,000 patients, the research team found that TMB thresholds used to predict immunotherapy benefits vary by cancer type, allowing for more tailored treatment approaches.

Another groundbreaking article published in Cancer Cell shed light on the relationship between mutation burden and anti-PD-1 outcomes. The study conducted by Caris and the POA revealed the cancer type-specific nature of immune markers, emphasizing the need for comprehensive, multiomic strategies in understanding treatment responses.

Caris has also published significant findings in the Journal of Clinical Oncology and Clinical Cancer Research, focusing on topics such as the concordance between next-generation sequencing and traditional methods for detecting microsatellite instability and the distinctive transcriptional profiles found in different subtypes of renal cell carcinoma.

The Caris POA is a global network of leading cancer centers and research entities that work collaboratively to foster advancement in precision oncology and biomarker-driven research. Their mission involves developing new standards for molecular testing to enhance clinical outcomes for cancer patients.

Founded to realize the potential of precision medicine, Caris Life Sciences is committed to improving the human condition through innovative solutions. They focus on comprehensive molecular profiling, advanced AI applications, and machine learning algorithms to analyze disease's molecular complexity.

Based in Irving, Texas, with additional offices in Phoenix, New York, Japan, and Switzerland, Caris serves clients in the U.S., Europe, and Asia, continually aiming to elevate the standards of care in precision medicine. Explore more about their innovative work at CarisLifeSciences.com.